GB2308362A - Pharmaceutical indole derivatives - Google Patents

Pharmaceutical indole derivatives Download PDF

Info

Publication number
GB2308362A
GB2308362A GB9525963A GB9525963A GB2308362A GB 2308362 A GB2308362 A GB 2308362A GB 9525963 A GB9525963 A GB 9525963A GB 9525963 A GB9525963 A GB 9525963A GB 2308362 A GB2308362 A GB 2308362A
Authority
GB
United Kingdom
Prior art keywords
prepared
mixture
ethanol
added
melting point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9525963A
Other versions
GB9525963D0 (en
Inventor
Peter Thaddeus Gallagher
William Martin Owton
Colin William Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Priority to GB9525963A priority Critical patent/GB2308362A/en
Publication of GB9525963D0 publication Critical patent/GB9525963D0/en
Priority to PE1996000916A priority patent/PE26198A1/en
Priority to CA002193039A priority patent/CA2193039C/en
Priority to PL96317526A priority patent/PL317526A1/en
Priority to MX9606531A priority patent/MX9606531A/en
Priority to AT96309200T priority patent/ATE204273T1/en
Priority to ES96309200T priority patent/ES2159693T3/en
Priority to IL11984496A priority patent/IL119844A/en
Priority to DK96309200T priority patent/DK0780388T3/en
Priority to PT96309200T priority patent/PT780388E/en
Priority to SG1996011771A priority patent/SG47206A1/en
Priority to EP96309200A priority patent/EP0780388B1/en
Priority to NZ299959A priority patent/NZ299959A/en
Priority to TR96/01018A priority patent/TR199601018A1/en
Priority to YU67096A priority patent/YU67096A/en
Priority to ZA9610589A priority patent/ZA9610589B/en
Priority to DE69614491T priority patent/DE69614491T2/en
Priority to ARP960105722A priority patent/AR010205A1/en
Priority to BR9606066A priority patent/BR9606066A/en
Priority to CZ963722A priority patent/CZ372296A3/en
Priority to NO965448A priority patent/NO307512B1/en
Priority to JP8337819A priority patent/JPH09202784A/en
Priority to HU9603498A priority patent/HUP9603498A3/en
Priority to KR1019960067182A priority patent/KR970042503A/en
Priority to CN96117941A priority patent/CN1157822A/en
Priority to AU75460/96A priority patent/AU720711B2/en
Priority to US08/833,239 priority patent/US5773448A/en
Publication of GB2308362A publication Critical patent/GB2308362A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)

Description

1--; 2308362 PHARMACEUTICAL COMPOUND This invention relates to
pharmaceutical compounds, their preparation and use.
in which The compounds of the invention are of the formula:
X R1 N- (CR6R7),, -W-Y-Z 12 FR 3 R R 4 R1 and R2 are each hydrogen, C1-4 alkyl, C1-4 alkoxy, HO-Cl-4 alkyl, C1-4 alkoxy-Cl-4 alkyl, C1-4 alkylthio, halo, Ph, PhCR'R''- where Ph is optionally substituted phenyl and R' and R'' are each hydrogen Or Cl-4 alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, >C=O, >C=NOR' where R' is hydrogen or C1-4 alkyl, R3, R4 and R5 are each hydrogen, halo, nitro, C1-4 alkyl, C1-4 alkoxy, C1- 4 alkylthio, C1-4 alkyl-CO-, C1-4 alkyl-S(O)mwhere m is 0, 1 or 2, RIRI'N- SO2-, -COOR', -CONROR11, -NRIRII, -N(ORI)C0ORI', -COR', -NHS02W, where R' and W' are each hydrogen or Cl-4 alkyl, G.1312 - 1) - R6 and R7 are each hydrogen or C1-4 alkyl, and n is 1 to 6, X is oxygen or sulphur, W is (CH2)q - N (CH2)p or -N N- (CH2)r where p is 4 to 7, and q and r are each 1 to 3, Y is.OCO or -CH (OH) and Z is optionally substituted phenyl or optionally substituted heteroaryl; and salts and esters thereof.
The compounds of the invention are indicated for use in the treatment of diseases of the central nervous system. They are active in tests that indicate serotonergic modulation.
G. 1312 In the above formula (I), a C1-4 alkyl group includes methyl, ethyl, propyl, isopropyl, butyl and tert. butyl, and is preferably methyl or ethyl. A C1-4 alkoxy group is one such alkyl group linked to a ring via an oxygen atom, and a halo atom is preferably chlorine, bromine or fluorine, and especially chlorine or fluorine. A substituted phenyl group is phenyl substituted with one or more, for example one to three, substituents selected from, for example C1-4 alkyl, especially methyl, C1-4 alkoxy, especially methoxy and ethoxy, hydroxy, nitro, cyano, halo, especially chloro or fluoro, trihalomethyl, especially trifluoromethyl, carboxy and C1-4 alkoxy- carbonyl.
A heteroaryl group can have one or more hetero atoms selected from, for example, oxygen, nitrogen and sulphur and preferably contains from 5 to 10 carbon atoms. Preferably a heteroaryl group is of the formula:
, 1) where Q is -0-, -S- or -NR-, and R is hydrogen or C1-6 alkyl. Alternatively, a heteroaryl group can comprise a benzene fused ring as, for example:
-70 Q G.1312 Further heteroaryl groups include those of the formula:
N , - J.1 N and When n is greater than 1, the values of R6 and R7 need not be identical in each repeating methylene unit.
Preferred compounds are those having one or more of the 10 following features:
(i) X is oxygen (ii) R1 and R2 are each hydrogen, C1-4 alkyl, C1-4 alkylthio or benzyl is (iii) R1 and R2 are both methyl (iv) RI is hydrogen and R2 is methyl (v) R3, R4 and R5 are each hydrogen, halo Or C1-4 alkyl (vi) R6 and R7 are both hydrogen (vii) n is 2 (viii) W is G.1312 /00' N (CH2)p (ix) p is 5 (x) Y is 14.1. CO (xi) Z is optionally substituted phenyl A preferred group of compounds is of the formula:
R' 0 R2 _ N- (CH2)n N..I R3 0 11 - Q-, c R8 (11) in which R1 and R2 are each hydrogen or C1-4 alkyl, R3 and R4 are each hydrogen, C1-4 alkyl or halo, n is 2, and R8 is hydrogen or halo. A particularly preferred group is one in which RI and R2 are both hydrogen and R3 is hydrogen or fluoro, n is 2 and R8 is halo, preferably fluoro; and salts thereof.
G. 1312 It will be appreciated that the compounds of the invention can contain one or more asymmetric carbon atoms which gives rise to isomers. The compounds are normally prepared as racemic mixtures and can conveniently be used as such, but individual isomers can be isolated by conventional techniques if so desired. Such racemic mixtures and individual optical isomers form part of the present invention. It is preferred to use an enantiomerically pure form.
it is, of course, possible to prepare salts of the compounds of the invention and such salts are included in the invention. Acid addition salts are preferably the pharmaceutically acceptable, nontoxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example, glycollic, maleic, hydroxymaleic, fumaric, malic, tartaric, citric, salicyclic, _Q-acetoxybenzoic, or organic sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic, or naphthalene-2-sulphonic acid.
In addition to pharmaceutically-acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically- G. 1312 7 - acceptable, acid addition salts, or are useful for identification, characterisation or purification.
The invention also includes a process for producing a compound of formula (1) above, which comprises reacting a compound of the formula H-W-Y-Z (III) with a compound of formula:
R1 X 2 AN- (CR 6 R7),,0 R 3 R RS R 4 OV) where the substituents have the values given above, and Q is a leaving group, for example, halo or a mesylate or tosylate.
The reaction is preferably carried out in an inert organic solvent such as, for example, methyl isobutyl ketone or acetonitrile, and at a temperature of from 800 C. to 1100 The reaction takes place in alkaline conditions by the use of, for example, sodium carbonate or potassium carbonate.
Compounds of formula (III) are either known or can be prepared by methods well known in the art.
In the case of compounds in which W is G. 1312 C.
(CH2)q N (CH2)r compounds can be prepared reacting the partially protected nitrogen containing cyclic amine with a phenyl or heteroaryl carbonyl halide, followed by deprotection, to give compounds of the formula:
(CH2)q 0 11 N-C-Z HN (CH2)r optionally followed by reduction to give the compound of formula (III) in which Y is -CH(OH)-.
Compounds of formula (IV) are either known or can be prepared by methods well known in the art as, for example, by reacting a compound of the formula:
G.1312 X R1 AN 1H 2 RW 3 J R5 W (V) with a compound of the formula Q'(CR6R7)nQ, where Q' is also a leaving group.
An alternative route to the compounds of the invention consists of an analogous, reverse, condensation of the principal components of the molecule as, for example, by reacting a compound of the formula (V) above, with a 10 compound of the formula Q (CR6R7) n-W-Y-Z Such reagents can be made as described above or by analogous 15 methods.
As mentioned above, the compounds of the invention have useful central nervous system activity. The compounds are active at the serotonin, 5HT1Da, receptor. Their binding activity has been demonstrated in a test described by Zgombick, J. M. et al., molecular Pharmacology Vol. 40 1992, pages 1036-1042, and compounds of the invention as described in the following Examples have a Ki of from 2 r1M to 5,000 r1M. Some of the compounds, for example those of G.1312 i - 10 formula III, also possess binding activity at the 5-HTII)p receptor. Furthermore, compounds have activity at the 5-HT2A receptors as shown in the test described by Leysen, J. E. et al., Molecular Pharmacology Vol. 21 1981, pages 301-314.
Because of their selective affinity for the 5HT receptors, the compounds of the present invention are indicated for use in treating a variety of conditions such as obesity, bulimia, alcoholism, pain, depression, hypertension, ageing, memory loss, sexual dysfunction, anxiety, schizophrenia, gastrointestinal disorders, headache, cardiovascular disorders, smoking cessation, drug addiction, emesis, Alzheimer's and sleep disorders.
is The compounds of the invention are effective over a wide dosage range, the actual dose administered being dependent on such factors as the particular compound being used, the condition being treated and the type and size of mammal being treated. However, the dosage required will normally fall within the range of 0.01 to 20 mg/kg per day, for example in the treatment of adult humans, dosages of from 0.5 to 100 mg per day may be used.
The compounds of the invention will normally be administered orally or by injection and, for this purpose, the compounds will usually be utilised in the form of a pharmaceutical composition. Such compositions are prepared in a manner G.1312 well known in the pharmaceutical art and comprise at least one active compound.
Accordingly the invention includes a pharmaceutical composition comprising as active ingredient a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, associated with a pharmaceutically acceptable excipient. In making the compositions of the invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. The excipient may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Some examples of suitable excipients are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl-hydroxybenzoate, talc, magnesium stearate or oil. The compositions of the invention may, if desired, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
Depending on the route of administration, the foregoing compositions may be formulated as tablets, capsules or suspensions for oral use and injection solutions or suspensions for parenteral use or as suppositories. Preferably the compositions are formulated in a dosage unit form, each dosage G. 1312 containing from 0.5 to 100 mg, more usually 1 to 100 mg, of the active ingredient.
The following Examples illustrate the invention:
G. 1312 EXAMPLE 1
2(3.3-Dimethvlo2gindolvl)ethano: 3,3-Dimethyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) was dissolved in dry dimethylformamide under nitrogen at room temperature. Sodium hydride (60% dispersion in mineral oil) (1.05 equivalents) was added and the mixture was stirred until gas evolution ceased. 2-(2-Chloroethoxy)tetrahydro-2H-pyran (1.05 equivalents) and Sodium iodide (0.1 equivalents) was added and the mixture was warmed to 750 C. for 15 hours. Water was added and the mixture was concentrated under reduced pressure. The residue was taken up in ethyl acetate, washed (x 3) with water, dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was taken up in methanol, paratoluenesulphonic acid (0.1 equivalents) was added and the mixture was stirred at room temperature for 12 hours. The mixture was concentrated under reduced pressure, taken up in ethyl acetate, washed (x 3) with aqueous sodium hydrogen carbonate solution dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was purified by chromatography on silica gel, eluent hexane/ethyl acetate, to give 2(3, 3dimethyloxindolyl)ethanol which was characterised by 1H nmr and MS.
1H NMR (CDC13) d 1.4(6H s), 3.05 (1H broad), 3.95(4H s), 6.96(1H d), 7. 04(1H t), 7.12(2H m).
G.1312 - 14 MS shows 206 (MHI) base peak.
1-{2-f4-(4-Fluorobenzovl)-1-r)ir>eridinyll-l-ethyll-3 3dimethyl-indol-2 (M) -one monohydrochlori e:-2(3,3Dimethyloxindolyl)ethanol and triethylamine (1.1 equivalents) was dissolved in dichloromethane under nitrogen and cooled to less than 50 C. in an ice/water bath. Methanesulfonyl chloride (1.05 equivalents) was added and the mixture was stirred for one hour with cooling. The mixture was washed with cold dilute hydrochloric acid, dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was dissolved in dry acetonitrile, 4-fluorobenzoylpiperidine (1 equivalent as its paratoluenesulfonate salt), potassium carbonate (3 equivalents) and potassium iodide (0.1 equivalents) were added. The mixture was stirred vigorously and heated under gentle reflux for two days. The mixture was poured into chloroform, washed with water, dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was taken up in 5N hydrochloric acid whereupon a white solid separated. This solid was recrystallised from ethanol to give 1-{2-[4-(4-fluorobenzoyl)-1- piperidinyll-l-ethyl)-3,3dimethyl-indol-2 (M) -one monohydrochloride. Melting point 236-80 C.
G. 1312 EXAMPLE
3-Methvl-3-methvlthiooxindole: Oxindole and tetramethylethylenediamine (2.2 equivalents) was dissolved in freshly distilled tetrahydrofuran under nitrogen and cooled to -750 C. in an acetone/dry ice bath.
n-Butyllithium (2.2 equivalents) was added and the mixture was stirred at -75 C. for 30 minutes. Iodomethane (1 equivalent) was added and the mixture was allowed to warm to -200 C, the mixture was recooled to -750 C. then dimethyl disulfide (1 equivalent) was added and the mixture was allowed to warm to room temperature. Water (5 ml) was added and the mixture was concentrated under reduced pressure to a yellow oil. Column chromatography on silica gel (eluent ethyl acetate/hexane) gave 3-methyl-3-methylthiooxindole as a yellow oil which solidified on standing.
1H NIMR (CDC13) d 1.61(3H s), 1.910H S), 6.96(1H d), 7.04(1H t), 7.12(2H m), 8.05 (1h broad).
2-(3-Methvl-3-methvlthiooxindolvl)ethano1: Prepared from 3-methyl-3methylthiooxindole and 2-(2chloroethoxy)tetrahydro-2H-pyran as described in Example 1.
MS shows 238 (MH+) base peak.
G.1312 1-f2-r4-(4-Fluorobenzovl)-1-piperidinyll-l-ethyll-3-methvl3-methvlthioindol-2(3H)-one monohydrochlori e: Prepared from 2-(3-methyl-3-methylthio oxindolyl)ethanol, via the methanesulfonate, and 4fluorobenzoylpiperidine tosylate as described in Example 1.
melting point 198-2010 C.
EXAMPLE
1-f2-F4-(4-Fluorobenzovl)-1-piperidinyll-l-ethvl}-3-met 1= indol-2(3H)one monohmdrochloride: 1-{2-[4-(4Fluorobenzoyl)-1-piperidinyll-l-ethyl}-3methyl-3- methyl thio- indol -2 (3H) -one was dissolved in ethanol, Raney Nickel was added and the mixture was stirred at room temperature until TLC indicated reaction was complete. The mixture was filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography on silica gel (eluent ethyl acetate/hexane). The resulting clear oil was dissolved in ethanol, ethanolic HCl was added and the mixture was concentrated under reduced pressure to give a white solid which recrystallised from 2 propanol to give 1 {2-[4-(4 Fluorobenzoyl) -1-piperidinyll -1-ethyl} -3-methyl-indol-2 (3H) - one monohydrochloride. Melting point 209-211 0 C.
G.1312 EXAMPLE -4
3-Benzvl-3-mgthvlthiooxin!dole 3-Benzyloxindole (prepared from oxindole and benzaldehyde by the method of Daisley and Walker J. Chem. Soc. (C) (1971) page 1373) and tetramethylethylenediamine (2.2 equivalents) was dissolved in freshly distilled tetrahydrofuran under nitrogen and cooled to -750 C. in an acetone/dry ice bath. n Butyllithium (2.2 equivalents) was added and the mixture was stirred at -750 C. for 30 minutes. Dimethyl disulfide (1 equivalent) was added and the mixture was allowed to warm to room temperature. Water (5 ml) was added and the mixture was concentrated under reduced pressure to a yellow oil. Column chromatography on silica gel (eluent ethyl acetate/hexane) gave 3 benzyl-3-methylthiooxindole as a yellow oil which solidified on standing.
H NMR (CDC13) d 1.910H s), 3.25(1H d), 3.42(1H d), 6.76(1H d), 6.94(1H t), 7.12(5H m), 7.20(1H t), 7.28(1H t), 8.08(1H 20 broad).
2-(3-Benzvl-3-methvlthiooxindolyl)ethanol: Prepared from 3 benzyl-3methylthiooxindole and 2-(2chloroethoxy)tetrahydro-2H-pyran as described in Example 1.
MS shows 314 (MH+) base peak.
G. 1312 - 18 1-(2-r4-(4-Fluorobenzovl)-1-piperidinyll-l-ethyll-3-benz 1= 3 -methyl thio- indol -2(3H) -one monohydrochlori e: Prepared from 2-(3-benzyl-3- methylthio oxindolyl)ethanol, via the methanesulfonate, and 4- fluorobenzoylpiperidine tosylate as described in Example 1.
Melting point 182-1840 C.
EXAMPLE 5
1- ( 2 - r 4- (4 -Fluorobenzoyl) -1-piperidinyl 1 - 1 ethyl 1 -3 -benz 1=. indol-2(3H)-one monohydrochloride: Prepared by Raney Nickel reduction of 1-{2-[4-(4-Fluorobenzoyl)-1-piperidinyll-l- ethyl} - 3 -benzyl -3 -methyl thio- indol -2 (3H) -one as described in Example 1.
melting point 213-2160 C.
EXAMPLE
3-Benzvl3-methyloxiiidole: 3-Benzyloxindole (prepared from oxindole and benzaldehyde by the method of Daisley and Walker J. Chem. Soc. (C) (1971) page 1373) and tetramethylethylenediamine (2.2 equivalents) was dissolved in freshly distilled tetrahydrofuran under nitrogen and cooled to -750 C. in an acetone/dry ice bath.
G.1312 n-Butyllithium (2.2 equivalents) was added and the mixture was stirred at -750 C. for 30 minutes. Iodomethane (1.1 equivalent) was added and the mixture was allowed to warm to room temperature. Water (5 ml) was added and the mixture 5 was concentrated under reduced pressure to a yellow oil. Column chromatography on silica gel (eluent ethyl acetatelhexane) gave 3- benzyl-3-methyloxindole as a yellow oil which solidified on standing.
MS shows 238 (MH+) base peak and 255 (M+NH4+).
2-(3-Benzvl-3-methyloxindolvl)ethanol: Prepared from 3-benzyl-3methyloxindole and 2-(2-chloroethoxy)tetrahyciro2H-pyran.
MS shows 282 (MH+) base peak.
I- ( 2 - r 4 - (4 -Fluorobenzovl) -1-Dir)eridinyl 1 -1 -ethyl} -3 J2enz l. = 3 -methyl -indol -2 OH) -one monohydrochlori e: Prepared from 20 2 - (3 -benzy1-3 -methyl oxindolyl) ethanol, via the methanesulfonate, and 4fluorobenzoylpiperidine tosylate.
Melting point 204-2070 C.
G.1312 EXAMPLE
2-(3-Methvl-3-ethyloxindolvl)ethanol: Prepared from 3-methyl-3ethyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) and 2-(2-chloroethoxy)tetrahydro-2Hpyran.
MS shows 220 (MH+) base peak.
1-{2-r4-(4Fluorobenzovl)-1-r)iperidinyll-l-ethyll-3meth 1=. 3-ethvl-indol2(3H)-one monohydrochlori e: Prepared from 2-(3-methyl-3ethyloxindolyl)ethanol, via the methanesulfonate, and 4fluorobenzoylpiperidine tosylate as 15 described above.
Melting point 210-2120 C.
EXAMPLE 8
3-Isor)ropvl-3-methvlthiooxindole: Prepared from 3-isopropyloxindole (prepared from oxindole and acetone by the method of Daisley and Walker, J. Chem. Soc. (C) (1971) page 1373) by the method described above for 3 benzyl3methylthiooxindole.
MS shows 222 (M+) base peak.
G.1312 2-(Isor)ropvl-3-methvlthiooxindolvl)ethanol 3-methyl-3-methylthiooxindole and 2-(2chloroethoxy)tetrahydro-2H-pyran.
Prepared from MS shows 266 (MH+) base peak.
1-f2-f4-(4-Fluorobenzovl)-1-pir)eridinyll-l-ethvll3= isopropvl3methvlthio-indol-2(3H)-one monohydrochlori e Prepared from 2-(3-isopropyl-3-methylthio oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoylpiperidine tosylate.
Melting point 150-1520 C.
EXAMPLE
1-f2-[4-(4-Fluorobenzovl)-1-r)ir)eridinyll-l-ethvl}-3isopropvl-indol-2(3H)-one monohydrochlori e: Prepared by Raney Nickel reduction of 1-{2-[4-(4-fluorobenzoyl)-1piperidinyll-l-ethyl}-3-isopropyl3-methylthioi ndol-2(3H) one as described above.
Melting point 207-2090 C.
G.1312 EXAMPLE-1
5-Bromo-3.3-dimethyloxindol: 3,3-Dimethyloxindole was dissolved in chloroform and stirred at room temperature under nitrogen. Bromine (1 equivalent) was added and the mixture was heated under reflux until HBr evolution ceased and the bromine colour was discharged from the solution. The solution was washed with sodium metabisulphite solution and sodium hydrogen carbonate solution, dried (M9S04), filtered and concentrated to dry under reduced pressure to give 5-bromo-3,3- dimethyloxindole as a yellow solid.
1H NMR (CDC13) d1.39 (6H s), 6.8 (1H d), 7.3 (2H m), 7.9 (1H broad) 2-(5-BroMo-3.3-dimethyloxindolvl)ethan 1 5-bromo-3,3-dimethyloxindole and 2-(2chloroethoxy)tetrahydro-2H-pyran.
Prepared from 1H NMR (CDC13) d1.39 (6H s), 3.05 (1H broad), 3.95(4H s), 6.8 (1H d), 7.3 (2H m), 1-(2-14-(4-Pluorobenzovl)-1-pir>eridinyll-l-ethyll-5-bromo= 3.3-dimethvlindol-2(3H)-one monohydrochlQri e: Prepared from 2-(5-bromo-3,3-dimethyl oxindolyl)ethanol, via the methanesulfonate, and 4fluorobenzoylpiperidine tosylate.
G.1312 Melting point 208-2110 EXAMPLE 11 c.
5-methanesulfonvl-3.3-dimethyloxindole: 5-Bromo-3,3dimethyloxindole was dissolved in freshly distilled tetrahydrofuran with tetramethylethylenediamine (2 equivalents) and was cooled to -750 C. under nitrogen.
nButyllithium (2.4 equivalents) was added and the mixture was stirred at 750 C. for 40 minutes. Dimethyl disulfide (1.2 equivalents) was added and the mixture was allowed to warm to room temperature. Water (5 ml) was added and the mixture was concentrated under reduced pressure, the resulting oil was taken up in dichloromethane, washed with dilute hydrochloric acid, dried (M9S04), filtered and concentrated to dry under reduced pressure. The resulting oil was taken up in acetic acid, sodium perborate (5 equivalents) was added and the mixture was stirred at 50 0 C.
overnight. The mixture was poured into water and extracted with ethyl acetate. The combined organic phases were washed with 2N sodium hydroxide solution, dried (M9S04), filtered and concentrated under reduced pressure. Column chromatography on silica gel (eluent ethyl acetate/hexane) gave 5methane sulfonyl -3,3-dimethyloxindole as a pale yellow solid.
MS shows 240 (MHI) base peak and 257 (M+NH4).
G.1312 - 24 2-(5-Methane sulfonvl-3.3-dimeth-vloxiridolvl)ethan 1: Prepared from 5- methanesulfonyl-3,3-dimethyloxindole and 2(2-chloroethoxy)tetrahydro-2H- pyran.
1H NMR (CDC13) d1A1 (6H s), 2.5 (1H broad), 3.05 OH s), 3.95(4H s), 7.18 (1H d), 7.76 (1H s), 7.84 (1H d) 1-f2-F4-(4-Flilorobenzovl)-1-piperidinyll-l-ethyll-5= methanesulfonvl-3.3-dimethvl-indol-2(3H):Q-ne monohydrochloride: Prepared from 2-(5-methanesulfonyl-3,3 dimethyl oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoyl piperidine tosylate.
Melting point 223-226 C.
EXAMPLE 12
2-(5-Fluoro-3.3-dimethyloxindolvl)ethanol: 5-Fluorooxindole (prepared according to the method of Clark et al., Synthesis (1991) 871) was dissolved in freshly distilled tetrahydrofuran with tetramethylethylenediamine (2 equivalents) and was cooled to -750 C. under nitrogen. 25 nButyllithium (2.4 equivalents) was added and the mixture was stirred at -750 C. for 40 minutes. Iodomethane (2.4 equivalents) was added and the mixture was allowed to warm to room temperature. After two hours' stirring at this G.1312 temperature, water (5 ml) was added and the mixture was concentrated under reduced pressure, the resulting oil was taken up in dichloromethane, washed with dilute hydrochloric acid, dried (M9S04), filtered and concentrated to dry under reduced pressure to give a yellow oil. This oil was dissolved in N-methylpyrrolidone and stirred at room temperature under nitrogen. Sodium hydride (1.1 equivalents) was added and the mixture was stirred until gas evolution ceased. 2-(2Chloroethoxy)tetrahydro-2H-pyran (1.05 equivalents) and Sodium Iodide (0.1 equivalents) was added and the mixture was warmed to 750 C. for 15 hours. Water was added and the mixture was concentrated under reduced pressure. The residue was taken up in ethyl acetate, washed (x 3) with water, dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was taken up in methanol, paratoluenesulphonic acid (0.1 equivalents) was added and the mixture was stirred at room temperature for 12 hours. The mixture was concentrated under reduced pressure, taken up in ethyl acetate. washed (x 3) with aqueous sodium hydrogen carbonate solution dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was purified by column chromatography on silica gel, (eluent hexane/ethyl acetate) to give 2(5fluoro-3,3-dimethyloxindolyl)ethanol as a yellow oil.
MS shows 224 (MH') base peak and 241 (M+NH4) G.1312 26 1-(2-14-(4-Fluorobenzovl)-1-piperidinyll-l-ethvl}-5-fluo o= 3.3-dimethvlindol-2 (M) -one monohydrochloride: Prepared from 2 (5-fluoro-3,3dimethyl oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoyl piperidine tosylate as described above.
Melting point 221-2230 C.
EXAMPLE 1
5.6-Difluorooxindole: 33-Difluoroacetonitrile was added dropwise to 90% fuming nitric acid stirred and cooled in an ice/water bath. After 15 hours, stirring the mixture was poured into water, neutralised with sodium bicarbonate and extracted into dichloromethane. The organic phase was dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was dissolved in boron trifluoride acetic acid complex, water (1 ml) was added and the mixture was heated under reflux for three hours. The mixture was poured into water, the pH was adjusted to pH4 and the mixture was extracted with ethyl acetate. The organic phase was dried (M9S04), filtered and concentrated under reduced pressure. The resulting oily solid was dissolved in acetic acid, iron powder was added and the mixture was heated under reflux for 1 hour. The mixture was filtered through Celite and concentrated under reduced pressure to a dark oil. Column G.1312 27 - chromatography on silica gel (eluent chloroform/methanol) gave 5,6- difluorooxindole as an orange solid.
1H NMR (CDC13) d 3.48(2H s), 6.7(1H dd), 7.05(1H dd), 8.65 (1H broad) 2-(5.6-]2ifluoro-3.3-dimethyloxindolvl)ethanol: Prepared from 5,6difluoro oxindole.
1H NMR (CDC13) d 1.38(6H s), 3.20(1H broad), 3.84(4H m), 6.7(1H dd), 7.03(1H dd) 1-(2r4-(4-Fluorobenzovl)-1-r)ir)eridinyll-i-ethyll-5-fluoro3.3dimethvlindol-2(3H)-one monohydrochlori e: Prepared from 2(5-fluoro-3,3-dimethyl oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoyl piperidine tosylate as described above.
Melting point 223-2250 C.
EXAMPLE 1
2-(4-Methoxy-3.3-dimethyloxindolvl)ethanol: Prepared from 4-methoxyoxindole (prepared according to the method of Clark et al., Synthesis (1991) 871).
G.1312 28 - 1H NMR (CDC13) d 1.42(6H s), 2.8(1H broad), 3.75(4H m), 3.8(3H s), 6. 57(2H t), 7.06(1H dd), 1-{2-14-(4-Fluorobenzovl)-1-r)iperidinyll-i-ethyll-4-methoxy,3.3-dimethvl-indol-2(3H)-one monohydrochlori e: Prepared from 2-(4methoxy-3,3-dimethyl oxindolyl)ethanol, via the methanesulfonate, and 4fluorobenzoyl piperidine tosylate.
Melting point 224-2270 C.
EXAMPLE 1
2(3.3.5-Trimethyloxindolvl)ethanol: Prepared from 3,3,5-trimethyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657).
MS shows 220 (MH+) base peak and 237 (M+NH4) 1-{2-[4-(4-Fluorobenzovl)-1-pilperidinyll-l-ethyll-3.3.5= trimethvl-indol2(3H)-one monohydrochlori e: Prepared from 2-(3,3,5-trimethyl oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoyl piperidine tosylate.
Melting point 228-230' C.
G.1312 EXAMPLE 16
2-(5-Chloro-3.3-dimeth-yloxindo-lvl)ethan 1: Prepared from 5 5-chloro-3,3dimethyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657).
1H NMR (CDC13) d1.39 (6H s), 3.05 (1H broad), 3.95(4H s), 6.8 (IH d), 7.3 (2H m), 1-{2-F4-(4-Fluorobenzovl)-l-oil2eridinyll-l-ethvl}-5-chlo o-3,3-dimethvl- indol-2(3H)-one monohydj:ochlori e: Prepared from 2(5-chloro-3,3-dimethyl oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoyl piperidine tosylate.
Melting point 175-1760 C.
EXAMPLE 17
2-(3.3.7-Trimethyloxindolvl)ethanol: Prepared from 3,3,7trimethyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657).
MS shows 220 (MH+) base peak and 237 (M+NH4) 1-(2-r4-(4-Fluorobenzovl)-1-r)ir>eridinyll-l-ethyll-3.3.7 trimethvl-indol2(3H)-one monohydrochloride: Prepared from G.1312 2-(3,3,7-trimethyl oxindolyl)ethanol, via the methanesulfonate, and 4- fluorobenzoyl piperidine tosylate.
Melting point 150-1520 C.
is EXAMPLE 1
2-(5-Methoxy-3.3-dimethyloxindolvl)ethanol: Prepared from 10 5-methoxy-3, 3-dimethyloxindole (prepared by the method of Endler and Becker; OrganicSyntheses Coll. vol. 4 page 657).
1H NMR (CDC13) 81.39 (6H s), 3.05 (1H broad), 3.820H s), 3.95M s), 6.8 (1H d), 7.3 (2H m), 1-f2-14-(4-Fluorobenzovl)-1-piperidinyll-l-ethyll-5-metho-xy3,3-dimethvlindol-2(3H)-one monohydrochlori e: Prepared from 2-(5-chloro-3,3-dimethyl oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoyl piperidine tosylate.
EXAMPLE 19
3,3,4Tgimethyloxindol and 3.3.6-Tri=thyloxindol:
Prepared from N-isobutyl-3-methylphenylhydrazide by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657 and separated by preparative HPLC.
G. 1312 Melting point - 3,3,4-Trimethyloxindole -1330 C.
Melting point - 3,3,6-Trimethyloxindole -1780 C.
2-(3.3.4-Trimethyloxindolvl)ethanol: Prepared from 3,3,4trimethyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) as described above.
MS shows 220 (MHI) base peak and 237 (M+NH4) 1{2-r4-(4Fluorobenzovl)-1-r)ir)eridinyll-l-ethyll-3,3 4.= trimethvl-indol2(3H)-one monohydrochloride: Prepared from 2-(3,3,4-trimethyl oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoyl piperidine tosylate as described above.
Melting point 211-2140 C.
EXAMPLE 20
2-(3-3.6-Trimethyloxindolvl)ethanol: Prepared from 3,3,6trimethyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) as described above.
MS shows 220 (MH+) base peak and 237 (M+NH4) G.1312 32 I-f2-[4-(4-Fluorobenzovl)-1-pir)eridinyll-l-ethyll-3.3 6= tl:imethvlindQl-2(3H) -one monohydrochloride: Prepared from 2-(3,3,6-trimethyl oxindolyl)ethanol, via the methanesulfonate, and 4-fluorobenzoyl piperidine tosylate as described above.
Melting point 198.5-200.5 is c.
EXAMPLE 21
1- (2 -Chloroethvl) -1. 3 -dihvdro-2H-indol-2 -one: 1-(2Chloroethyl)-1Hindole-2,3-dione [C.A. Reg no. 77218-99-61 was suspended in acetic acid and hydrogenated at 60 p.s.i., at room temperature, in the presence of 70% perchloric acid and 5% palladium on charcoal for 24 hours. The clear solution was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel, eluent chloroform, to give 1-(2-Chloroethyl)1,3-dihydro-2H- indol-2-one as a white solid.
Melting point 740 C.
1-f2-[4-(4-Fluorobenzovl)-1-i)iperidinyll-l-ethy-l}-1 3=.
dihydro-2H- indQ1-2 -one hydrochloride: 1-(2-Chloroethyl)1,3-dihydro-2Hindol-2-one and 4-fluorobenzoyl piperidine (1 equivalent as its paratoluenesulponate salt) were added to a G.1312 - 33 solution of sodium carbonate (8 equivalents) and water. The mixture was stirred mechanically at reflux for 9 hours. The hot solution was cooled (ice-water bath) and the hard solid was broken up, filtered, washed with water and dried. The 5 solid was purified by chromatography on silica gel, eluent chloroform-1% methanol, to give an oil. The pure freebase was dissolved in a little chloroform, ethanolic HCl was added, the solution was evaporated to dryness and triturated with ether to give 1-{2-[4-(4fluorobenzoyl)-1-piperidinyll 1-ethyl}1,3-dihydro-2H-indol-2-one hydrochloride as a white solid.
Melting point 2050 C.
EXAMPLE 2
1-(2-Chloroethvl)-5-fluoro-1H-indole-2.3-dio e 5-Fluoroisatin was dissolved in dimethylformamide. Sodium hydride (60% dispersion in mineral oil)(1.2 equivalents) was added in portions with stirring and cooling (ice-water bath) and the mixture was stirred until gas evolution ceased.
1-Bromo-2-chloroethane (1.2 equivalents) was added dropwise. The mixture was stirred at room temperature for 24 hours and then quenched into water and extracted into chloroform. The combined organic phases were washed with water, dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was purified by chromatography on silica G. 1312 34 gel, eluent chloroform, to give 1-(2-Chloroethyl)-5-fluoro1H-indole-2,3- dione as a red solid.
Melting point 1030 C.
1-(2-chloroethvl)-1.3-dihvclro-5-fluoro-2-oxo-2H-indole-3.z spiro-2'-1.3 dithiang A solution of 1-(2-chloroethyl)-5-fluoro-1H-indole-2,3- dione, propanedithiol (1.2 equvalents) in chloroform was added dropwise to a stirred solution of boron trifluoride etherate in acetic acid and chloroform which was maintained at a gentle reflux throughout the addition. After 6 hours, reaction the mixture was cooled, washed with water and sodium hydrogen carbonate solution, dried (M9S04) and filtered through a pad of flash silica using chloroform as eluent. The combined fractions were evaporated under reduced pressure to give 1-(2chloroethyl)-1,3-dihydro-5fluoro-2-oxo-2H-indole-3-spiro-2'-1,3 dithiane.
Melting point 1220 C.
EXAMPLE 2
1- (2-Chloroethyl) -5-f luoro-l. 3 -dihydro-2H-indole-2 -one: 1-(2chloroethyl)-1,3-dihydro-5-fluoro2-oxo-2H-indole3spiro21-1,3 dithiane was dissolved in a mixture of G.1312 ethanol/tetrahydrofuran (3:2). Raney nickel was added and the mixture was heated under reflux with vigorous stirring for 3 hours. The cooled solution was filtered, evaporated under reduced pressure and triturated with ether to give 1-(2-Chloroethyl)-5-fluoro-1,3-dihydro-2H-indole-2-one as a white solid.
Melting point 1270 C.
1-{2-r4-(4-Fluorobenzovl)-1-r)iperidinyll-l-ethyll-5-fluo o1,3-dihvdro-2H-indol-2-one hydrochlori e: Prepared from 1-(2-chloroethyl)5-fluoro-1,3-dihydro-2H-indole-2-one and 4-fluorobenzoyl piperidine (1 equivalent as its paratoluenesulponate salt) by the aqueous coupling procedure 15 described above.
Melting point 221-2230 C.
EXAMPLE 2
1-(2-Chloroethvl)-3.3-difluorooxindole:1-(2-Chloroethyl)1H-indole-2,3dione [C.A. Reg no. 77218-99-6] was heated to 65 0 C. under nitrogen in diethylaminosulfur trifluoride.
The reaction mixture was poured onto water and extracted with chloroform. The organic phase was washed with sodium hydrogen carbonate solution, dried (M9S04) and filtered to give 1-(2-chloroethyl)-3,3-difluorooxindole as a dark oil.
G. 1312 - 36 MS shows 231 and 233 (MH+) 1{2- r4- (4-Fluorobenzoyl) -I -Dir)eridinyl I -1-ethyl I -3,3= difluoro-indol-2(3H)-one monohydrochlori e 1-(2-Chloroethyl)-3,3-difluorooxindole, 4-fluorobenzoyl piperidine (1 equivalent as its paratoluenesulponate salt), potassium carbonate (3 equivalents) and potassium iodide (0.1 equivalents) were dissolved in N-methyl pyrrolidone and heated with stirring to 850 C. for 6 hours. The reaction mixture was poured into water and extracted into ethyl acetate. dried (M9S04), filtered and concentrated under reduced pressure. The resulting oil was purified by chromatography on silica gel, eluent hexane/ethyl acetate, to give a yellow oil. The oil was dissolved in ethanol, ethanolic HCl was added and the mixture was concentrated under reduced pressure to give a white solid. This was taken up in hot ethyl acetate and refrigerated whereupon a white solid precipitated, this was collected by filtration to give 1- {2 - [ 4 - (4-Fluorobenzoyl) -1-piperidinyl] -1 -ethyl} - 3,3-difluoro-indol-2(3H)-one monohydro chloride.
Melting point 202-2050 C.
G. 1312 - 37 EXAMPLF2 1-(2-Chloroethvl)-3,3,5-triifluorooxindo e: Prepared from 1-(2-chloroethyl)-5-fluoro-1H-indole-2,3-dione and diethylaminosulfur trifluoride.
MS shows 249 and 251 (MH+) 1-{2-F4-(4-Fluorobenzovl)-1-r)iperidinyll-l-ethyll-3.3 5=.
trifluoro-indol-2(3H)-one monchydrochlori e 1-(2-chloroethyl)-3,3,5trifluorooxindole and 4-fluorobenzoyl piperidine.
Melting point 209-2120 EXAMPLE 26
C.
Prepared from 3-Cvcloi2ropyl oXindol: 60% Sodium hydride (2.4 g, 60 mmols) was suspended in dimethylformamide (15 mls) and cooled to 0 0 C. N-acetyl oxindole (prepared by the method of Robertson et al., J. Med. Chem. 1986 page 1832) was added dropwise as a dimethylformamide(80 mls) solution over 20 minutes. Mixture stirred at ambient temperature for 20 minutes then 1, 2-dibromoethane added dropwise at 100 C. Mixture stirred at ambient temperature for 48 hours. Water (20 mls) added and mixture concentrated in vacuo. 0.5 M G. 1312 hydrochloric acid (80 mls) added and mixture extracted with chloroform (2 x 100 mls). Washed with 0.5 M hydrochloric acid (3 x 50 mls) and brine (50 mls). Dried over magnesium sulphate, filtered and concentrated in vacuo then columned on flash silica eluent chloroform-2% methanol.
1H NMR (CDC13) 81.54 (2H M), 1.78 (2H m), 6.82 (1H d), 7.02 (2H m), 7.22 (1H m), 9.0 (1H broad) EXAMPLE 27
2-(3-cvcloipror)vl oxindo1Y1)ethanol: Prepared from 3-cyclopropyloxindole and 2-(2-chloroethoxy)tetrahydro-2H15 pyran.
1H NMR (CDC13) 81.54 (2H m), 1.78 (2H m), 3.85 (4H m), 6.82 (1H d), 7.02 (2H m), 7.22 (1H m) 1-(2-(4-(4-fluorobenzovl)-1oiperidinvl)-1-ethvl)-1.3= dihvdro-3-spiro-l-cvclopror)vl2H-irtdole-2-o e monohydrochloridp.: Prepared from 2-(3-cyclopropyl oxindolyl)ethanol via the methanesulfonate, and 4-fluorobenzoylpiperidine tosylate.
Melting point 238-2400 C.
G. 1312 39 - EXAMPLE 2
2-(3Phenvl-3-methyloxindolvl)ethanol: Prepared from 3 phenyl -3 methyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) and 2-(2-chloroethoxy)tetrahydro-2Hpyran.
1H NMR (CDC13) 81.78 (3H s), 6.82 (1H d), 7.02 (2H m), 7.22 (1H m), 7.3 (5H m), 9.25 (1H broad) 1-(2-(4-(4-fluorobenzovl)-1-piperidinvl)-1-ethvl)-3-met 1 3-phenvl-1,3dihvdro-2H-indol-2-one monohydrochloride Prepared from 2 - (3 -phenyl -3 methyloxindolyl) ethanol via the methanesulfonate, and 4fluorobenzoylpiperidine tosylate.
Melting point 215-216 0 C.
EXAMPLE 2
Tablets each containing 10 mg of active ingredient are made up as follows:
G.1312 - Active ingredient 10 mg Starch 160 mg Microcrystalline cellulose 100 mg Polyvinylpyrrolidone (as 10% solution in water) 13 mg Sodium carboxymethyl starch 14 mg Magnesium stearate 3 mg Total 300 mg The active ingredient, starch and cellulose are mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders and passed through a sieve. The granules so produced are dried and re-passed through a 15 sieve. The sodium carboxymethyl starch and magnesium stearate are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 300 mg.
EXAMPLE 3
Capsules each containing 20 mg of medicament are made as follows:
G.1312 - 41 Active ingredient Dried starch Magnesium stearate Total mg 17 8 mg 2 mg mg The active ingredient, starch and magnesium stearate are passed through a sieve and filled into hard gelatine 10 capsules in 200 mg quantities.
G.1312 - 42 CLA A compound of the formula:
X R1 N - (CR6R7), -W-Y-Z R2 R 3 R R 4 (1) in which RI and R2 are each hydrogen, C1-4 alkyl, C1-4 alkoxy, HO-Cl-4 alkyl, C1-4 alkoxy-Cl-4 alkyl, C1-4 alkylthio, halo, Ph, PhCR'R''- where Ph is optionally substituted phenyl and R ' and R 1 are each hydrogen or C1-4 alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, >C=O, >C=NOR' where R' is hydrogen or C1-4 alkyl, R3, R4 and R5 are each hydrogen, halo, nitro, C1-4 alkyl, C1-4 alkoxy, C1- 4 alkylthio, C1-4 alkyl-CO-, C1-4 alkyl-S(O)m- where m is 0, 1 or 2, R1R1IN-SO2-, -COOR' -CONR@Rlt, -DM#Rlf, -N(OR)C0OR'', -CORI, -NHS02R', where R' and R' 1 are each hydrogen or C1-4 alkyl, R6 and R7 are each hydrogen or C1-4 alkyl, and n is 1 to 6, G.1312 X is oxygen or sulphur, W is is (CH2)q - N (CH2)p or -N (CH2)r where p is 4 to 7, and q and r are each 1 to 3, Y is 'CO or -CH (OH) 101 and Z is optionally substituted phenyl or optionally substituted heteroaryl; and salts and esters thereof.
A compound according to claim 1 in which X is oxygen and W is:
G.1312 (CH2)p "I - 44 3. A compound according to either of claims 1 and 2 in which Z is optionally substituted phenyl.
4. A compound of the formula:
is 0 R1 0 r 11 c (CH2)n - N -,,,,,) R8 (11) in which R1 and R2 are each hydrogen or Cl-4 alkyl, R3 and R4 are each hydrogen, C1-4 alkyl or halo, n is 2, and R8 is hydrogen or halo. A particularly preferred group is one in which RI and R2 are both methyl, or R1 is hydrogen and R2 is methyl, R3 and R4 are both hydrogen, n is 2 and R8 is halo, preferably fluoro, and salts thereof.
5. A compound according to claim 1 or a pharmaceuticallyacceptable salt or ester thereof, for use as a pharmaceutical.
6. A pharmaceutical formulation comprising a compound according to claim 1 or a pharmaceutically-acceptable salt or ester thereof together with a pharmaceuticallyacceptable carrier or diluent therefor.
G. 1312
GB9525963A 1995-12-19 1995-12-19 Pharmaceutical indole derivatives Withdrawn GB2308362A (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GB9525963A GB2308362A (en) 1995-12-19 1995-12-19 Pharmaceutical indole derivatives
PE1996000916A PE26198A1 (en) 1995-12-19 1996-12-16 PHARMACEUTICAL COMPOUNDS
CA002193039A CA2193039C (en) 1995-12-19 1996-12-16 Indol-2-one derivatives
ARP960105722A AR010205A1 (en) 1995-12-19 1996-12-17 A PHARMACEUTICAL COMPOUND
NZ299959A NZ299959A (en) 1995-12-19 1996-12-17 Indole-2-one derivatives, preparation and medicaments for treating central nervous system diseases
DE69614491T DE69614491T2 (en) 1995-12-19 1996-12-17 5HT1Dalpha and 5HT2A Ligande
AT96309200T ATE204273T1 (en) 1995-12-19 1996-12-17 5HT1DALPHA AND 5HT2A LIGANDS
ES96309200T ES2159693T3 (en) 1995-12-19 1996-12-17 LIGANDOS 5HT1DALFA AND 5HT2A.
IL11984496A IL119844A (en) 1995-12-19 1996-12-17 Substituted indole derivatives and pharmaceutical compositions containing them
DK96309200T DK0780388T3 (en) 1995-12-19 1996-12-17 5HT1Dalfa and 5HT2A ligands
PT96309200T PT780388E (en) 1995-12-19 1996-12-17 5HT1DALFA AND 5HT2 LIGANDS
SG1996011771A SG47206A1 (en) 1995-12-19 1996-12-17 Pharmaceutical compounds
EP96309200A EP0780388B1 (en) 1995-12-19 1996-12-17 5HT1Dalpha and 5HT2A ligands
PL96317526A PL317526A1 (en) 1995-12-19 1996-12-17 Pharmaceutic compounds
TR96/01018A TR199601018A1 (en) 1995-12-19 1996-12-17 Pharmaceutical compounds.
YU67096A YU67096A (en) 1995-12-19 1996-12-17 Pharmaceutical compounds
ZA9610589A ZA9610589B (en) 1995-12-19 1996-12-17 Pharmaceutical compounds.
MX9606531A MX9606531A (en) 1995-12-19 1996-12-17 Pharmaceutical compounds.
CN96117941A CN1157822A (en) 1995-12-19 1996-12-18 Pharmaceutical compounds
BR9606066A BR9606066A (en) 1995-12-19 1996-12-18 Compound and pharmaceutical formulation
CZ963722A CZ372296A3 (en) 1995-12-19 1996-12-18 Pharmaceutical compounds
NO965448A NO307512B1 (en) 1995-12-19 1996-12-18 New indole compounds, pharmaceutical preparations containing such compounds, and their use
JP8337819A JPH09202784A (en) 1995-12-19 1996-12-18 Pharmaceutical compound
HU9603498A HUP9603498A3 (en) 1995-12-19 1996-12-18 Indole derivatives and pharmaceutical compositions containing them
KR1019960067182A KR970042503A (en) 1995-12-19 1996-12-18 Pharmaceutical compound
AU75460/96A AU720711B2 (en) 1995-12-19 1996-12-19 Pharmaceutical compounds
US08/833,239 US5773448A (en) 1995-12-19 1997-04-14 Pharmaceutical compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9525963A GB2308362A (en) 1995-12-19 1995-12-19 Pharmaceutical indole derivatives

Publications (2)

Publication Number Publication Date
GB9525963D0 GB9525963D0 (en) 1996-02-21
GB2308362A true GB2308362A (en) 1997-06-25

Family

ID=10785702

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9525963A Withdrawn GB2308362A (en) 1995-12-19 1995-12-19 Pharmaceutical indole derivatives

Country Status (27)

Country Link
US (1) US5773448A (en)
EP (1) EP0780388B1 (en)
JP (1) JPH09202784A (en)
KR (1) KR970042503A (en)
CN (1) CN1157822A (en)
AR (1) AR010205A1 (en)
AT (1) ATE204273T1 (en)
AU (1) AU720711B2 (en)
BR (1) BR9606066A (en)
CA (1) CA2193039C (en)
CZ (1) CZ372296A3 (en)
DE (1) DE69614491T2 (en)
DK (1) DK0780388T3 (en)
ES (1) ES2159693T3 (en)
GB (1) GB2308362A (en)
HU (1) HUP9603498A3 (en)
IL (1) IL119844A (en)
MX (1) MX9606531A (en)
NO (1) NO307512B1 (en)
NZ (1) NZ299959A (en)
PE (1) PE26198A1 (en)
PL (1) PL317526A1 (en)
PT (1) PT780388E (en)
SG (1) SG47206A1 (en)
TR (1) TR199601018A1 (en)
YU (1) YU67096A (en)
ZA (1) ZA9610589B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810886D0 (en) * 1998-05-13 1998-07-22 Lilly Industries Ltd Pharmaceutical compounds
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN106928122A (en) * 2017-03-07 2017-07-07 贵州大学 3 alkoxy quaternary carbon Oxoindoles and preparation method thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4035369A (en) * 1975-10-08 1977-07-12 Janssen Pharmaceutica N.V. 1-Benzazolylalkyl-4-substituted-piperidines
US4432978A (en) * 1979-07-30 1984-02-21 Pfizer Inc. Hexahydro-trans-pyridoindole
US4254127A (en) * 1980-04-03 1981-03-03 Janssen Pharmaceutica, N.V. 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
FR2523964B1 (en) * 1982-03-23 1985-09-27 Sanofi Sa NOVEL TRYPTAMINE DERIVATIVES ACTIVE IN PARTICULAR ON THE CARDIOVASCULAR SYSTEM AND PROCESS FOR THEIR PREPARATION
IL69132A (en) * 1982-07-14 1986-02-28 Roussel Uclaf Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them
US4658038A (en) * 1982-10-07 1987-04-14 Research Foundation For Mental Hygiene, Inc. N-acylated 5-hydroxytryptophan amide derivatives
US4608374A (en) * 1983-11-07 1986-08-26 Hoechst-Roussel Pharmaceuticals Inc. 11-substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines as antipsychotic and analgesic agents
GB8332704D0 (en) * 1983-12-07 1984-01-11 Pfizer Ltd Growth promotants for animals
DE3563964D1 (en) * 1984-10-16 1988-09-01 Synthelabo Piperidine derivatives, their preparation and their therapeutical application
US4789676A (en) * 1986-03-05 1988-12-06 Merrell Dow Pharmaceuticals Inc. Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives, usefull as anxiolytic agents
EP0351283A1 (en) * 1988-07-12 1990-01-17 Synthelabo 2-[(4-Piperidinyl)methyl]-2,3-dihydro-1H-isoindole and 2,3,4,5-tetrahydro-1H-benzazepine derivatives, their preparation and therapeutical use
FR2634207B1 (en) * 1988-07-12 1990-09-07 Synthelabo ((PIPERIDINYL-4) METHYL) BENZAZEPINES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2635524B1 (en) * 1988-08-19 1992-04-24 Adir NOVEL BENZOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
TW203049B (en) * 1990-04-13 1993-04-01 Yamanouchi Pharma Co Ltd
FR2661177A1 (en) * 1990-04-23 1991-10-25 Rhone Poulenc Sante DERIVATIVES OF NAPHTOSULTAM ANTAGONISTS OF SEROTONIN, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
FR2679561A1 (en) * 1991-07-26 1993-01-29 Schneider Marc New (1-indolyl)alkylamine derivatives substituted by a chain having carbonyl groups conjugated with an aromatic ring
SE9103752D0 (en) 1991-12-18 1991-12-18 Astra Ab NEW COMPOUNDS
TW218875B (en) * 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
CA2092112A1 (en) * 1992-03-23 1993-09-24 Nobuyoshi Iwata Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use
EP0572235A3 (en) * 1992-05-28 1994-06-01 Tanabe Seiyaku Co Beta-carboline derivatives with anticholecystoquinine activity
EP0669830A4 (en) * 1992-11-06 1997-02-26 Merck & Co Inc Substituted dipeptide analogs promote release of growth hormone.
CZ151495A3 (en) * 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
IL112112A (en) * 1993-12-23 2000-06-29 Novo Nordisk As Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
RU2167881C2 (en) * 1993-12-23 2001-05-27 Ново Нордиск А/С Compounds promoting growth hormone release
GB9418326D0 (en) * 1994-09-12 1994-11-02 Lilly Industries Ltd Pharmaceutical compounds
ATE247114T1 (en) * 1994-09-12 2003-08-15 Lilly Co Eli SEROTONERGIC MODULATORS
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues

Also Published As

Publication number Publication date
AU720711B2 (en) 2000-06-08
PL317526A1 (en) 1997-06-23
KR970042503A (en) 1997-07-24
HU9603498D0 (en) 1997-02-28
DE69614491D1 (en) 2001-09-20
TR199601018A1 (en) 1997-07-21
HUP9603498A3 (en) 2001-04-28
NO965448L (en) 1997-06-20
NO307512B1 (en) 2000-04-17
IL119844A0 (en) 1997-03-18
EP0780388B1 (en) 2001-08-16
ES2159693T3 (en) 2001-10-16
AR010205A1 (en) 2000-06-07
CZ372296A3 (en) 1997-08-13
GB9525963D0 (en) 1996-02-21
NZ299959A (en) 1998-09-24
CA2193039C (en) 2006-04-04
MX9606531A (en) 1997-06-28
EP0780388A1 (en) 1997-06-25
BR9606066A (en) 1998-09-01
NO965448D0 (en) 1996-12-18
US5773448A (en) 1998-06-30
AU7546096A (en) 1997-06-26
SG47206A1 (en) 1998-03-20
IL119844A (en) 2000-12-06
PT780388E (en) 2001-12-28
DE69614491T2 (en) 2002-04-18
HUP9603498A2 (en) 1998-09-28
CN1157822A (en) 1997-08-27
ZA9610589B (en) 1998-01-16
ATE204273T1 (en) 2001-09-15
CA2193039A1 (en) 1997-06-20
JPH09202784A (en) 1997-08-05
YU67096A (en) 1999-03-04
PE26198A1 (en) 1998-05-27
DK0780388T3 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
ES2223536T3 (en) GAMMA-CARBOLINS CONDENSED WITH REPLACED HETEROCICLES.
US6166040A (en) Indole compounds
JP4964380B2 (en) Tricyclic derivative of pyrazole carboxylic acid, process for producing the same and pharmaceutical composition containing the same
US7592454B2 (en) Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
DE69226867T2 (en) PIPERIDE DERIVATIVES WITH ANXIOLYTIC EFFECT
JP2756742B2 (en) N-acyl-2,3-benzodiazepine derivatives, method for producing the same, pharmaceutical compositions containing the same, and methods for producing the same
DK167572B1 (en) 6-SUBSTITUTED 4-AMINOTETRAHYDROBENZOEC, DAE INDOLES, PROCEDURES FOR PREPARING IT, AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH INDOLS
AU698580B2 (en) Serotonergic tetrahydropyridoindoles
NO326443B1 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
AU716435B2 (en) Novel indole-2,3-dione-3-oxime derivatives
JPH11502861A (en) Substituted benzolactam compounds as substance P antagonists
CA1337202C (en) Cyclic amides which are leukotriene antagonists
US5929072A (en) 1H-2,1,3-benzothiadiazine-2,2-dioxide compounds or derivatives thereof
US6407112B1 (en) Optically active tetrahydrobenzindole derivative
JP2015521990A (en) Indene derivatives, their production and use as pharmaceuticals
GB2308362A (en) Pharmaceutical indole derivatives
GB2362381A (en) Pharmaceutically active indolyl-piperidines
JPH09506083A (en) Phenylindole compounds
CA1337770C (en) Hydrocarbon substituted pyrrolidinones
AU661076B2 (en) Indole derivatives
MXPA96006531A (en) Pharmaceutical compounds
FI94863B (en) Process for the preparation of therapeutically useful halo-3,4-dihydrobenzothiopyranylamines
AU628735B2 (en) Cerebral function enhancing pyrimidinyl derivatives
US6844338B2 (en) Piperidyindoles as serotonin receptor ligands

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)